HSA/FSA-eligible products available
Medical Supplies for Home
#1021215560 | Mfg #1001-0613 | Clinical Laboratory

Anitgen Detection Control Kit IntelliSwab® COVID-19 Rapid Test Pro Positive Level, Negative Level

CONTROLS, F/COVID-19 TEST INT ELISWAB EXTERNAL KIT/BOX D/S
Anitgen Detection Control Kit IntelliSwab® COVID-19 Rapid Test Pro Positive Level, Negative Level

The InteliSwab® COVID-19 Rapid Test Pro is for use under the Food and Drug Administration’s Emergency Use Authorization (EUA) only: https://www.fda.gov/medical-devices/coronavirus-disease-2019-covid-19-emergency-use-authorizations-medical-devices/in-vitro-diagnostics-euas-antigen-diagnostic-tests-sars-cov-2

Product Specifications

MSFH #
1021215560
Manufacturer #
1001-0613
Brand
IntelliSwab®
Manufacturer
Orasure Technologies
Country of Origin
United States
Application
Control Kit
Container Type
Vial
For Use With
For use with IntelliSwab COVID-19 Rapid Test Kit
HCPCS
U0002
Levels
Positive Level, Negative Level
Product Dating
McKesson Acceptable Dating: we will ship >= 90 days
Storage Requirements
Requires Refrigeration
Test Name
COVID-19 Rapid Test Pro
Test Type
Anitgen Detection
UNSPSC Code
41116205

Description

Kit contains: InteliSwab® COVID-19 Positive Control (1 vial, blue cap, 0.25 mL), InteliSwab® COVID-19 Negative Control (1 vial, white cap, 0.25 mL), Loops (package of 5 µL loops), Instructions for use for InteliSwab® COVID-19 Rapid Test Pro Kit Controls

Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform moderate, high or waived complexity tests

This test is authorized for use at the Point of Care (POC), i.e., in patient care settings operating under a CLIA Certificate of Waiver, Certificate of Compliance, or Certificate of Accreditation

Laboratories within the United States and its territories are required to report all results to the appropriate public health authorities in accordance with local, state, and federal requirements using appropriate LOINC and SNOMED codes, as defined by the Laboratory In Vitro Diagnostics (LVID) Test Code Mapping for SARS-CoV-2 Tests provided by CDC

Positive results indicate that viral antigens have been detected, but clinical correlation with patient history and other diagnostic information is necessary to determine infection status; positive results do not exclude bacterial infection or coinfection with other viruses

Negative results should be treated as presumptive and confirmation with a molecular assay, if necessary, for patient management, may be performed; negative results do not rule out SARS-CoV-2 infection and should not be used as the sole basis for treatment or patient management decisions, including infection control decisions

Negative results should be considered in the context of an individual’s recent exposures, history and the presence of clinical signs and symptoms consistent with COVID-19

The InteliSwab™ COVID-19 Rapid Test Pro is intended for use by medical professionals or trained operators who are proficient in performing tests and trained clinical laboratory personnel or individuals trained in POC settings